Georgia's Online Cancer Information Center


back

Unknown Primary Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Unknown Primary
Cancer Type = Unknown Primary
NCI ID Cancer Type Trial Name
There are currently 223 active Unknown Primary clinical trials in Georgia.
NCI ID Cancer Type Trial Name
1.
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT05186753
Protocol IDs
CGT9486-21-202
NCI-2022-01167
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
2.
6-Hour Oxaliplatin in Preventing Nerve Damage in Patients with Advanced or Metastatic Gastrointestinal Cancer
Cancer Type
Unknown Primary
NCT ID
NCT03800693
Protocol IDs
Winship4468-18
NCI-2018-02241
IRB00106610
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
3.
A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Cancer Type
Melanoma, Unknown Primary
NCT ID
NCT05933577
Protocol IDs
V940-001
NCI-2023-05647
2023-503652-27-00
V940-001
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
4.
A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma
Cancer Type
Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT05323253
Protocol IDs
CTP-SCC-03
NCI-2022-10859
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
5.
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT06270706
Protocol IDs
PLN-101095-ONC-101
NCI-2024-01965
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
6.
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05150691
Protocol IDs
DB-1303-O-1001
NCI-2022-04237
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
7.
A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05972720
Protocol IDs
CRG-022-101
NCI-2023-06284
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
8.
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Cancer Type
Eye Cancer, Melanoma, Unknown Primary
NCT ID
NCT06007690
Protocol IDs
AU-011-301
NCI-2023-07465
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
9.
NCORP Trial
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type
Melanoma, Unknown Primary
NCT ID
NCT02339571
Protocol IDs
EA6141
NCI-2014-02674
Treatment Sites (5)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
10.
NCORP Trial
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT06112379
Protocol IDs
D926QC00001
NCI-2024-01327
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
11.
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT05482971
Protocol IDs
EXCEED ET / A22-301
NCI-2023-00605
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
12.
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
Cancer Type
Unknown Primary
NCT ID
NCT05171075
Protocol IDs
ANT-008
NCI-2022-08854
2021-003085-12
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
13.
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT05459129
Protocol IDs
CO43613
NCI-2022-06114
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
14.
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT05646862
Protocol IDs
WO43919
NCI-2023-01628
2022-502322-41-00
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
15.
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04712097
Protocol IDs
GO42909
NCI-2021-09247
2020-005239-53
16.
A Study of a New Way to Treat Children and Young Adults with a Brain Tumor Called NGGCT
Cancer Type
Germ Cell Tumor, Gestational trophoblastic disease, Testicular Cancer, Unknown Primary
NCT ID
NCT04684368
Protocol IDs
ACNS2021
ACNS2021
NCI-2020-13175
17.
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Cancer Type
Bladder Cancer, Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Unknown Primary
NCT ID
NCT06120075
Protocol IDs
ARC-27
NCI-2024-03901
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
18.
NCORP Trial
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
Cancer Type
Ovarian Cancer, Solid Tumor, Unknown Primary, Uterine Cancer
NCT ID
NCT05548296
Protocol IDs
ACR-368-201 (GOG 3082)
NCI-2022-10629
Treatment Sites (2)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
19.
A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT06188559
Protocol IDs
BB-1701-G000-205
NCI-2024-00539
2023-506866-30
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
20.
A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03571568
Protocol IDs
17-BI1206-02
NCI-2018-02697
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
21.
A Study of Combination Chemotherapy for Patients with Newly Diagnosed DAWT and Relapsed FHWT
Cancer Type
Brain Tumor, Unknown Primary, Wilms Tumor
NCT ID
NCT04322318
Protocol IDs
AREN1921
AREN1921
NCI-2020-01561
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
22.
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCT ID
NCT04104776
Protocol IDs
0209-01
NCI-2020-01007
23.
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
Cancer Type
Hematopoietic Malignancies, Unknown Primary
NCT ID
NCT05250973
Protocol IDs
CR109160
NCI-2022-01987
2021-002639-48
54767414AMY2009
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
24.
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT05629585
Protocol IDs
D926XC00001
NCI-2023-00614
2022-002680-30
Treatment Sites (2)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
25.
NCORP Trial
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT06018337
Protocol IDs
DB-1303-O-3002
NCI-2024-02685
CTR20233708
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
26.
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT06064877
Protocol IDs
AV-299-23-301
NCI-2024-00596
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
27.
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT05805501
Protocol IDs
BO43936
NCI-2023-03569
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
28.
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
Cancer Type
Unknown Primary
NCT ID
NCT05263999
Protocol IDs
EQ-100-02
NCI-2022-02430
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
29.
A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05614739
Protocol IDs
LOXO-FG3-22001
NCI-2023-00367
022-502755-59-00
2022-502755-59-00
J4G-OX-JZVA
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
30.
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05293496
Protocol IDs
CP-MGC018-02
NCI-2022-04067
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
31.
A Study of NKT2152, a HIF2a Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT05119335
Protocol IDs
NKT2152-101
NCI-2021-13434
32.
A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT06063317
Protocol IDs
CF33-CD19-101
NCI-2023-08528
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
33.
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05787587
Protocol IDs
IDE161-001
NCI-2023-03139
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
34.
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCT ID
NCT05487170
Protocol IDs
RNK05047-01
NCI-2022-09252
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
35.
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Cancer Type
Brain & Spinal Cord Tumor, Colon/Rectal Cancer, Head and Neck Cancer, Lung Cancer, Neuroendocrine Tumor, Solid Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT03157128
Protocol IDs
LOXO-RET-17001
NCI-2017-00976
2017-000800-59
Treatment Sites (1)
Emory University School of Medicine
Atlanta
36.
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
Cancer Type
Unknown Primary
NCT ID
NCT04683003
Protocol IDs
TAK-755-3002
NCI-2021-13466
2020-003348-10
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
37.
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04919512
Protocol IDs
CR109044
NCI-2022-05645
17000139BLC2002
2020-005565-13
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
38.
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT05714202
Protocol IDs
CR109223
NCI-2023-05193
17000139BLC3002
2020-004506-64
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
39.
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04658862
Protocol IDs
CR108917
NCI-2021-10015
17000139BLC3001
2020-002620-36
40.
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT05253651
Protocol IDs
SGNTUC-029
NCI-2022-07692
2021-002672-40
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
41.
A Study of XMT-1660 in Participants With Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05377996
Protocol IDs
MER-XMT-1660-1
NCI-2022-04696
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
42.
NCORP Trial
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
Cancer Type
Unknown Primary, Uterine Cancer
NCT ID
NCT04814108
Protocol IDs
ZN-c3-004
NCI-2021-11201
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
43.
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05907304
Protocol IDs
ERAS-254-01
NCI-2024-00013
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
44.
A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT04546399
Protocol IDs
AALL1821
AALL1821
NCI-2020-06813
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
45.
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients with High Risk Rhabdomyosarcoma
Cancer Type
Sarcoma, Unknown Primary
NCT ID
NCT04994132
Protocol IDs
ARST2031
ARST2031
NCI-2021-06711
46.
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Cancer Type
Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary
NCT ID
NCT05675410
Protocol IDs
AHOD2131
AHOD2131
NCI-2022-10845
47.
A Study to Compare Treatment with the Drug Selumetinib Alone versus Selumetinib and Vinblastine in Patients with Recurrent or Progressive Low-Grade Glioma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
NCT ID
NCT04576117
Protocol IDs
ACNS1931
ACNS1931
NCI-2020-07549
48.
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05451810
Protocol IDs
M23-362
NCI-2022-09111
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
49.
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT06065748
Protocol IDs
CO44657
NCI-2024-00434
2022-502980-39-00
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
50.
NCORP Trial
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04970901
Protocol IDs
ADCT-402-105
NCI-2022-04828
2021-001071-16
Treatment Sites (2)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
51.
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05581004
Protocol IDs
GO43860
NCI-2022-08852
2021-006708-34
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
52.
A Study to Examine Computerized Training to Improve Concentration, Learning New Things, and Remembering in Stage I-III Breast Cancer Survivors
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT05896189
Protocol IDs
NRG-CC011
NRG-CC011
NRG-CC011
NCI-2023-06537
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
53.
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT06008093
Protocol IDs
D419ML00003
NCI-2024-00168
Treatment Sites (1)
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
54.
A Study to Learn More About the Health of Persons with Down Syndrome After Treatment for Acute Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT05702645
Protocol IDs
ALTE22C1
ALTE22C1
ALTE22C1
NCI-2022-09410
55.
A Study to See if Memantine Protects the Brain during Radiation Therapy Treatment for Primary Central Nervous System Tumors
Cancer Type
Unknown Primary
NCT ID
NCT04939597
Protocol IDs
ACCL2031
ACCL2031
COG-ACCL2031
NCI-2020-07502
56.
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
Cancer Type
Unknown Primary
NCT ID
NCT06143891
Protocol IDs
EFC17757
NCI-2023-10169
2023-505394-32
U1111-1280-4918
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
57.
A Study with Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Cancer Type
Hematopoietic Malignancies, Unknown Primary
NCT ID
NCT05828069
Protocol IDs
ANHL2121
ANHL2121
NCI-2022-06282
NCT05287295
58.
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT06091254
Protocol IDs
R1979-HM-2298
NCI-2024-00238
2022-502660-20-00
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
59.
NCORP Trial
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04673617
Protocol IDs
AB-101-01
NCI-2021-00532
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
60.
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04883437
Protocol IDs
WINSHIP5186-20
NCI-2021-00894
STUDY00002247
61.
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05653271
Protocol IDs
ACE1831-001
NCI-2023-03335
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
62.
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT05952557
Protocol IDs
D8535C00001
NCI-2023-06834
2023-504031-41-00
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
63.
An Internet-Based Application for Improving Adherence to Endocrine Therapy among Patients with Early Stage Hormone Receptor Positive, HER2-Negative Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT05488145
Protocol IDs
WINSHIP5532-22
NCI-2022-03205
STUDY00004350
Treatment Sites (4)
Emory Johns Creek Hospital
Johns Creek
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
64.
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05011058
Protocol IDs
VT3996-202
NCI-2021-09770
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
65.
ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT04662580
Protocol IDs
ARX517-2011
NCI-2021-03637
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
66.
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed At Least Two Lines of Therapy
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03769506
Protocol IDs
ASP-1929-301
NCI-2019-01324
67.
Atezolizumab for the Treatment of Patients with Resectable, Human Papillomavirus Related Oropharyngeal Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT06254911
Protocol IDs
WINSHIP5730-22
NCI-2023-01367
STUDY00004678
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
68.
Biomarker-Driven Radiation Therapy Dose Reduction after Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT05387915
Protocol IDs
WINSHIP5566-22
NCI-2022-02855
STUDY00004187
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
69.
NCORP Trial
Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor, Unknown Primary
NCT ID
NCT04955808
Protocol IDs
DCP-002
DCP-002
DCP-002
NCI-2017-01572
70.
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated with Brentuximab Vedotin or Checkpoint Inhibitors
Cancer Type
Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary
NCT ID
NCT05039073
Protocol IDs
WINSHIP5260-21
NCI-2021-01655
STUDY00002348
Treatment Sites (2)
Emory Saint Joseph's Hospital
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
71.
Brentuximab Vedotin and Nivolumab with or without Ipilimumab in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary
NCT ID
NCT01896999
Protocol IDs
NCI-2013-01275
U10CA021115
E4412
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
72.
Cabozantinib and Isotretinoin in Treating Children with Relapsed or Refractory Solid Tumors
Cancer Type
Brain & Spinal Cord Tumor, Solid Tumor, Unknown Primary
NCT ID
NCT03611595
Protocol IDs
171971
NCI-2018-02497
73.
Cabozantinib in Combination with Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04878029
Protocol IDs
WINSHIP5259-21
NCI-2021-01365
STUDY00002329
74.
Cabozantinib or Sunitinib Malate in Treating Participants with Metastatic Variant Histology Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT03541902
Protocol IDs
2017-0725
NCI-2018-01041
75.
CAR-T Long Term Follow Up (LTFU) Study
Cancer Type
Unknown Primary
NCT ID
NCT02445222
Protocol IDs
CCTL019A2205B
NCI-2015-01238
2014-001673-14
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
76.
Cemiplimab before and after Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer
Cancer Type
Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT04428671
Protocol IDs
Winship4851-19
NCI-2019-07373
IRB00115160
77.
Chemotherapy for the Treatment of Patients with Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Cancer Type
Sarcoma, Unknown Primary
NCT ID
NCT05304585
Protocol IDs
ARST2032
ARST2032
NCI-2022-01012
78.
Collecting Blood Samples from Patients with and without Cancer to Evaluate Tests for Early Cancer Detection
Cancer Type
Breast Cancer, Head and Neck Cancer, Hematopoietic Malignancies, Kidney Cancer, Leukemia, Melanoma, Sarcoma, Solid Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT05334069
Protocol IDs
A212102
A212102
A212102
NCI-2022-02477
Treatment Sites (1)
Low Country Cancer Care Associates, PC
Savannah
79.
NCORP Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients with Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT02997228
Protocol IDs
NRG-GI004
NRG-GI004
NCI-2016-01961
NRG-GI004/S1610
Treatment Sites (4)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
Southern Regional Medical Center
Riverdale
Stephen Cohen, MD
770-997-1975
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
80.
Combining Radiation Therapy with Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT05721755
Protocol IDs
EA3211
EA3211
NCI-2022-10141
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
81.
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined with Radiation for Patients with Advanced Head and Neck Cancer
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT05050162
Protocol IDs
NRG-HN009
NRG-HN009
NCI-2021-08925
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
82.
NCORP Trial
Comparing Overall Survival using Markers to Direct Cancer Monitoring versus Usual Monitoring in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT03723928
Protocol IDs
S1703
S1703
SWOG-S1703
NCI-2018-00090
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
83.
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Cancer Type
Esophogeal Cancer, Unknown Primary
NCT ID
NCT03801876
Protocol IDs
NRG-GI006
NRG-GI006
NCI-2018-03378
84.
Comparing the Addition of Radiation either before or after Surgery for Patients with Brain Metastases
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCT ID
NCT05438212
Protocol IDs
NRG-BN012
NRG-BN012
NCI-2022-04804
Treatment Sites (1)
Piedmont Columbus Regional
Columbus
85.
Comparing the Outcome of Standard Systemic Therapy Only versus Standard Systemic Therapy with Either Surgery or Radiation Therapy, for Patients with Advanced Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT03678025
Protocol IDs
S1802
S1802
NCI-2018-01738
Treatment Sites (2)
Emory Saint Joseph's Hospital
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
86.
Comparing Two Methods to Follow Patients with Pancreatic Cysts
Cancer Type
Unknown Primary
NCT ID
NCT04239573
Protocol IDs
EA2185
EA2185
ECOG-ACRIN-EA2185
NCI-2019-04790
87.
NCORP Trial
Comparison of Chemotherapy before and after Surgery versus after Surgery Alone for the Treatment of Gallbladder Cancer, OPT-IN Trial
Cancer Type
Gallbladder Cancer, Unknown Primary
NCT ID
NCT04559139
Protocol IDs
EA2197
EA2197
NCI-2020-05162
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
88.
CX-4945 in Treating Patients with Recurrent SHH Medulloblastoma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
NCT ID
NCT03904862
Protocol IDs
PBTC-053
PBTC-053
NCI-2019-00180
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
89.
DALY II USA/ MB-CART2019.1 for DLBCL
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04792489
Protocol IDs
M-2018-344
NCI-2021-08357
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
90.
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
Cancer Type
Neuroendocrine Tumor, Unknown Primary
NCT ID
NCT06132113
Protocol IDs
1438-0007
NCI-2024-00432
2023-505870-13-00
U1111-1292-1400
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
91.
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT05555732
Protocol IDs
DS1062-A-U303
NCI-2023-06122
2022-500802-16-00
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
92.
De-intensified Radiation Therapy with Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients with Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT03952585
Protocol IDs
NRG-HN005
NRG-HN005
NCI-2019-03015
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Grady Memorial Hospital
Atlanta
93.
Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT06216574
Protocol IDs
WF-2202
WF-2202
WF-2202
NCI-2023-06866
94.
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT04567420
Protocol IDs
DARE
NCI-2021-03770
95.
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Unknown Primary
NCT ID
NCT05118841
Protocol IDs
ZX-4081
NCI-2022-02249
96.
Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04652960
Protocol IDs
10347
10347
NCI-2020-11641
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
97.
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients with Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04890236
Protocol IDs
Winship5085-20
NCI-2020-06380
STUDY00001001
98.
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
Cancer Type
Anal Cancer, Unknown Primary
NCT ID
NCT04444921
Protocol IDs
EA2176
EA2176
NCI-2020-04334
Treatment Sites (1)
Lewis Hall Singletary Oncology Center at John D. Archbold Memorial Hospital
Thomasville
99.
Educational Interview in Improving Health Literacy in African-American Participants with Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT03322891
Protocol IDs
HU-HEALTHLITERACY
NCI-2018-00842
IRB00091879
IRB00085616
Treatment Sites (4)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Atlanta
Atlanta
Grady Memorial Hospital
Atlanta
100.
NCORP Trial
EHR Tool in Assessing Heart Health among Cancer Survivors
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Prostate Cancer , Solid Tumor, Unknown Primary, Uterine Cancer
NCT ID
NCT03935282
Protocol IDs
WF-1804CD
WF-1804CD
WF-1804CD
NCI-2019-01362
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
101.
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
Cancer Type
Unknown Primary
NCT ID
NCT04620239
Protocol IDs
CLIN2001 UCM301
NCI-2021-07136
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
102.
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT05696626
Protocol IDs
SMX 22-002
NCI-2023-09871
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
103.
Everolimus, Nelarabine, Cyclophosphamide, and Etoposide Phosphate in Treating Patients with Relapsed or Refractory T Cell Lymphoblastic Leukemia or Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03328104
Protocol IDs
AflacLL1602
NCI-2017-01717
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
104.
Fatigue Assessment in Patients with Breast Cancer Undergoing Chemotherapy, Surgery, or Radiation Therapy
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT02759549
Protocol IDs
WCI1651-09
NCI-2016-00824
IRB00028295
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
105.
NCORP Trial
Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT04960787
Protocol IDs
S1912CD
S1912CD
SWOG-S1912CD
NCI-2021-00579
Treatment Sites (2)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
106.
First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05103046
Protocol IDs
UCT03008-001
NCI-2021-14000
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
107.
Fluciclovine F18 or Gallium Ga 68-labeled PSMA-11 PET/CT in Enhancing Outcomes in Patients with Prostate Adenocarcinoma
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT03762759
Protocol IDs
RAD4516-18
NCI-2018-02702
IRB00106863
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Grady Memorial Hospital
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
108.
Gene Expression in Blood Samples from High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT00967239
Protocol IDs
MC083I
NCI-2009-01112
CDR0000638644
NSABP-MC083I
109.
Genetic Testing in Guiding Treatment for Patients with Brain Metastases
Cancer Type
Brain & Spinal Cord Tumor, Solid Tumor, Unknown Primary
NCT ID
NCT03994796
Protocol IDs
A071701
A071701
NCI-2019-00744
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
110.
Genetic Testing in Screening Patients with Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT03765736
Protocol IDs
ACCRU-GI-1611
NCI-2018-02862
111.
NCORP Trial NCI Priority
Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT02194738
Protocol IDs
NCI-2014-01509
A151216
U10CA180821
U10CA031946
Treatment Sites (27)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Cancer Center at DeKalb Medical Center
Decatur
Cathy Comer
404-501-7789
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Gwinnett Medical Center
Lawrenceville
404-851-2340
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Low Country Cancer Care Associates, PC
Savannah
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
Piedmont Columbus Regional
Columbus
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
112.
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05659381
Protocol IDs
GOG-3068
NCI-2023-08813
217908
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
113.
Immune Checkpoint Inhibitors with or without Propranolol Hydrochloride for the Treatment of Urothelial Cancer
Cancer Type
Unknown Primary
NCT ID
NCT04848519
Protocol IDs
WINSHIP5200-20
NCI-2021-00437
114.
Inotuzumab Ozogamicin and Blinatumomab in Treating Patients with Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT03739814
Protocol IDs
A041703
A041703
NCI-2018-02484
115.
Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02981628
Protocol IDs
AALL1621
AALL1621
NCI-2016-01494
AALL1621
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
116.
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Cancer Type
Hematopoietic Malignancies, Unknown Primary
NCT ID
NCT04754945
Protocol IDs
Winship5086-20
NCI-2020-06548
117.
KZR-261 in Subjects With Advanced Solid Malignancies
Cancer Type
Colon/Rectal Cancer, Eye Cancer, Melanoma, Prostate Cancer , Solid Tumor, Unknown Primary
NCT ID
NCT05047536
Protocol IDs
KZR-261-101
NCI-2022-01096
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
118.
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT04428151
Protocol IDs
7902-009
NCI-2020-04563
2019-000569-19
E7080-G000-228
LEAP-009
MK-7902-009
119.
Lenvatinib and Pembrolizumab before Surgery for the Treatment of Locally Advanced Non-Metastatic Kidney Cancer
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT04393350
Protocol IDs
Winship4955-20
NCI-2020-01064
120.
NCORP Trial
Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT04095364
Protocol IDs
NRG-GY019
NRG-GY019
NCI-2019-01460
Treatment Sites (4)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
121.
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Cancer Type
Unknown Primary
NCT ID
NCT03435796
Protocol IDs
GC-LTFU-001
NCI-2018-00957
U1111-1206-8250
2017-001465-24
122.
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Cancer Type
Unknown Primary
NCT ID
NCT03486873
Protocol IDs
3475-587
2017-004417-42
NCI-2018-01717
MK-3475-587
Treatment Sites (10)
Emory University School of Medicine
Atlanta
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
123.
NCORP Trial
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT03053193
Protocol IDs
FLEX Registry
NCI-2018-02995
Treatment Sites (6)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
Piedmont Cancer Institute - Atlanta
Atlanta
Katie Adams
678-298-3238
Piedmont Cancer Institute - Fayetteville
Fayetteville
678-298-3238
Piedmont Cancer Institute - Newnan
Newnan
Katie Adams
678-298-3238
Piedmont Cancer Institute - Stockbridge
Stockbridge
Katie Adams
678-298-3238
124.
Message-Based Communication Outreach Intervention in Engaging Ovarian Cancer Survivors and Relatives to Consider Genetic Screening Services
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT04927013
Protocol IDs
RSPH4984-20
NCI-2020-02281
STUDY00000224
125.
Metformin for the Prevention of Oral Cancer in Patients with Oral Leukoplakia or Erythroplakia
Cancer Type
Unknown Primary
NCT ID
NCT05237960
Protocol IDs
Pending12
UAZ21-07-01
NCI-2022-00596
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
126.
NCORP Trial
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05445778
Protocol IDs
IMGN853-0421
NCI-2023-00369
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
127.
NCORP Trial
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT05568472
Protocol IDs
SWOG-S2010
S2010
SWOG-S2010
NCI-2022-06902
Treatment Sites (2)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
128.
Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
Cancer Type
Cancer-Related Syndrome, Unknown Primary
NCT ID
NCT03150914
Protocol IDs
RLDC5713
NCI-2019-08422
U01HL131755-01
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
129.
Niraparib and Panitumumab in Treating Patients with Advanced or Metastatic Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT03983993
Protocol IDs
Winship4517-18
NCI-2018-02757
IRB00107377
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
130.
Nivolumab in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04759586
Protocol IDs
ANHL1931
ANHL1931
NCI-2021-01071
131.
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05664217
Protocol IDs
18-255-01
NCI-2023-02609
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
132.
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT06016738
Protocol IDs
OP-1250-301
NCI-2023-09687
OPERA-01
Treatment Sites (2)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
133.
NCORP Trial
Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT04181060
Protocol IDs
EA5182
EA5182
NCI-2019-07941
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
134.
Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
Cancer Type
Unknown Primary
NCT ID
NCT05866302
Protocol IDs
UMCC 2022.052
NCI-2023-05585
HUM00225273
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
135.
Paricalcitol and Hydroxychloroquine in Combination with Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced or Metastatic Pancreatic Cancer
Cancer Type
Pancreatic Cancer, Unknown Primary
NCT ID
NCT04524702
Protocol IDs
Winship5079-20
NCI-2020-05417
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Saint Joseph's Hospital of Atlanta
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
136.
Peginterferon alfa-2b in Treating Younger Patients with Recurrent or Refractory and Radiographically or Clinically Progressive Pilocytic Astrocytomas and Optic Pathway Gliomas
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Cancer-Related Syndrome, Unknown Primary
NCT ID
NCT02343224
Protocol IDs
IRB00074563
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
137.
NCORP Trial
Pembrolizumab versus Observation in Patients with Early Stage Triple-Negative Breast Cancer who had a Pathologic Complete Response after Chemotherapy plus Pembrolizumab, OptimICE-PCR Trial
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT05812807
Protocol IDs
A012103
A012103
NCI-2022-07859
Treatment Sites (3)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
138.
Pepinemab with or without Ipilimumab and/or Nivolumab in Treating Patients with Stage I-IVA Head and Neck Squamous Cell Cancer
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03690986
Protocol IDs
Winship4402-18
NCI-2018-01263
IRB00103534
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
139.
Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients with Low Testosterone
Cancer Type
Unknown Primary
NCT ID
NCT04731376
Protocol IDs
EU5097-20
NCI-2020-06998
140.
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT03785249
Protocol IDs
849-001
NCI-2019-01032
Treatment Sites (10)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
141.
Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors
Cancer Type
Brain & Spinal Cord Tumor, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Solid Tumor, Unknown Primary
NCT ID
NCT05098132
Protocol IDs
STK-012-101
NCI-2022-00633
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
142.
Poly ICLC for the Treatment of Progressive or Recurrent Low-Grade Gliomas in Children and Young Adults with Neurofibromatosis Type 1
Cancer Type
Brain & Spinal Cord Tumor, Cancer-Related Syndrome, Unknown Primary
NCT ID
NCT04544007
Protocol IDs
NF111
NCI-2022-03434
143.
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCT ID
NCT04365374
Protocol IDs
GTM-102
NCI-2021-03480
144.
NCORP Trial
Project: Every Child for Younger Patients with Cancer
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Leukemia, Neuroendocrine Tumor, Solid Tumor, Unknown Primary
NCT ID
NCT02402244
Protocol IDs
APEC14B1
NCI-2014-02057
Treatment Sites (2)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
145.
Proton Radiation Therapy for the Treatment of Patients with High Risk Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT04725903
Protocol IDs
RAD5131-20
NCI-2020-07113
146.
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05639751
Protocol IDs
PRT3789-01
NCI-2023-01949
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
147.
PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT06074510
Protocol IDs
PYL4301
NCI-2024-00237
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
148.
Radioligand Therapy after PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients with Biochemically Recurrent Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT06105918
Protocol IDs
RAD5633-23
NCI-2023-03480
STUDY00005677
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
149.
Reaching Rural Cancer Survivors Who Smoke
Cancer Type
Unknown Primary
NCT ID
NCT05008848
Protocol IDs
A211901
A211901
A211901
NCI-2021-03543
150.
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients with Newly Diagnosed WNT-Driven Medulloblastoma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
NCT ID
NCT02724579
Protocol IDs
ACNS1422
ACNS1422
NCI-2016-00150
ACNS1422
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
151.
Reduction of Donor Blood Transfusion in Patients During Surgery for in Patients with Locally Advanced Kidney Cancer
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT04922307
Protocol IDs
VICCURO2114
NCI-2021-10595
152.
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
Cancer Type
Liver Cancer / Hepatoblastoma, Unknown Primary
NCT ID
NCT05194293
Protocol IDs
ACCRU-GI-1920
NCI-2021-12021
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
153.
NCORP Trial
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05257408
Protocol IDs
CORT125134-556
NCI-2022-07960
GOG-3073
Treatment Sites (2)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
154.
Rituximab with or without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03267433
Protocol IDs
EA4151
EA4151
NCI-2016-01403
EA4151
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
155.
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
Cancer Type
Unknown Primary
NCT ID
NCT01656603
Protocol IDs
6637-01
NCI-2016-01676
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
156.
NCORP Trial
Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Cancer Type
Unknown Primary, Uterine Cancer
NCT ID
NCT05611931
Protocol IDs
XPORT-EC-042
NCI-2023-01755
ENGOT-EN20
GOG-3083
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
157.
NCORP Trial
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT05929768
Protocol IDs
S2212
S2212
NCI-2023-02688
Treatment Sites (2)
Lewis Hall Singletary Oncology Center at John D. Archbold Memorial Hospital
Thomasville
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
158.
Smoke-Free Homes Intervention for the Prevention of Smoking
Cancer Type
Unknown Primary
NCT ID
NCT04547686
Protocol IDs
SFH-5A-RCT
NCI-2021-01784
STUDY00001085
159.
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT04185883
Protocol IDs
20190135
NCI-2020-00134
2023-506794-35
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
160.
Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients with Brain Tumors
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCT ID
NCT04908709
Protocol IDs
RAD4500-18
NCI-2018-02065
IRB00106849
161.
Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab for the Treatment of Locally Advanced or Metastatic Cancer
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT04295863
Protocol IDs
IRB19-1718
NCI-2020-13885
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
162.
Stereotactic Radiosurgery or Hippocampus Avoidance Whole-Brain Radiation Therapy with Memantine in Treating Patients with 5 or more Brain Metastases
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCT ID
NCT03550391
Protocol IDs
CCTG CE.7
CE.7
CCTG CE.7
NCI-2018-00395
Treatment Sites (2)
Emory Saint Joseph's Hospital
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
163.
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT06267729
Protocol IDs
D9660C00001
NCI-2024-01754
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
164.
Study of CHS-114 in Participants With Advanced Solid Tumors
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Solid Tumor, Unknown Primary
NCT ID
NCT05635643
Protocol IDs
SRF114-101
NCI-2023-05019
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
165.
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04452591
Protocol IDs
CG3002S
NCI-2021-01691
166.
Study of INCB123667 in Subjects With Advanced Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05238922
Protocol IDs
INCB 123667-101
NCI-2022-03370
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
167.
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT04699188
Protocol IDs
CJDQ443A12101
NCI-2021-01594
168.
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Cancer Type
Cervical Cancer, Unknown Primary
NCT ID
NCT03108495
Protocol IDs
C-145-04
NCI-2017-01051
2016-003447-11
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
169.
NCORP Trial
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Cancer Type
Unknown Primary, Uterine Cancer
NCT ID
NCT05797831
Protocol IDs
KRT-232-118
NCI-2024-03038
ENGOT en-21
GOG-3089
170.
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Cancer Type
Unknown Primary
NCT ID
NCT03547973
Protocol IDs
IMMU-132-06 - TROPHY U-01
NCI-2018-03421
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
171.
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Cancer Type
Cervical Cancer, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Melanoma, Sarcoma, Skin Cancer (Non-Melanoma), Solid Tumor, Unknown Primary
NCT ID
NCT05103345
Protocol IDs
SGN-P01-002
NCI-2023-06281
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
172.
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05409066
Protocol IDs
M20-638
NCI-2022-09448
2021-000169-34
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
173.
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Cancer Type
Brain & Spinal Cord Tumor, Hematopoietic Malignancies, Lymphoma, Unknown Primary
NCT ID
NCT04947319
Protocol IDs
ONO-4059-09
NCI-2021-14196
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
174.
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT05433142
Protocol IDs
XmAb819-01
NCI-2022-05582
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
175.
Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05067257
Protocol IDs
RTX-CAP-201
NCI-2022-04731
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
176.
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT04428788
Protocol IDs
CC-94676-PCA-001
NCI-2020-13275
U1111-1251-9174
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
177.
Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04315324
Protocol IDs
S1905
S1905
NCI-2020-00768
178.
Sublobar Resection or Stereotactic Ablative Radiotherapy in Treating Patients with Stage I Non-small Cell Lung Cancer, The STABLE-MATES Trial
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT02468024
Protocol IDs
SCCC-02515; STU 022015-069
NCI-2015-01676
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
179.
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05910801
Protocol IDs
ACCRU-LY-2101
NCI-2023-03968
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
180.
Testing Continuous versus Intermittent Treatment with the Study Drug Zanubrutinib for Older Patients with Previously Untreated Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05976763
Protocol IDs
A052101
A052101
NCI-2023-03577
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
181.
NCORP Trial
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT01810913
Protocol IDs
RTOG 1216
NCI-2013-00500
U10CA021661
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
182.
Testing Drug Treatments after CAR T-cell Therapy in Patients with Diffuse Large B-cell Lymphoma That Has Come Back or Not Responded to Treatment
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05633615
Protocol IDs
S2114
S2114
NCI-2022-07930
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
183.
NCORP Trial
Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT03811015
Protocol IDs
EA3161
EA3161
NCI-2019-00179
Treatment Sites (4)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
184.
Testing Nivolumab with or without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Cancer Type
Unknown Primary, Uterine Cancer
NCT ID
NCT05112601
Protocol IDs
NRG-GY025
NRG-GY025
NCI-2021-11881
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
185.
NCORP Trial
Testing Olaparib and Temozolomide versus the Usual Treatment for Uterine Leiomyosarcoma after Chemotherapy Has Stopped Working
Cancer Type
Sarcoma, Unknown Primary, Uterine Cancer
NCT ID
NCT05432791
Protocol IDs
A092104
A092104
NCI-2022-05065
NCT05432791
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
186.
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients with High Risk Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT05946213
Protocol IDs
NRG-GU013
NRG-GU013
NCI-2023-04142
Treatment Sites (4)
Emory Proton Therapy Center
Atlanta
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
187.
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) after Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT05610163
Protocol IDs
A022104
A022104
NCI-2022-07800
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University